Home › Funds › Bleichroeder LP › CUE
Bleichroeder LP position in CUE
Cue Biopharma Inc · Health Care
Bleichroeder LP reported holding 366,152 shares of CUE (Cue Biopharma Inc) in its Q3 2026 13F filing — a position valued at US$9.5M, representing 0.95% of its reported portfolio and ranking #40 among its reported holdings. Bleichroeder LP has disclosed CUE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Bleichroeder LP's CUE position evolved
Bleichroeder LP first disclosed a stake in CUE in Q3 2023 at 755,028 shares (US$1.7M). The position peaked in Q2 2026 at 370,682 shares, worth US$11.7M. Across 13 filings, Bleichroeder LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 366,152 shares valued at US$9.5M — a reduction of -4,530 shares quarter over quarter.. Notable position changes include a 132% increase in Q4 2023 (shares fell 28% over the following quarter), a 75% increase in Q3 2024 (shares rose 44% over the following quarter), a 95% trim in Q2 2026 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 755.03K | $1.74M | New |
| Q4 2023 | 1.76M | $4.63M | Add |
| Q1 2024 | 2.76M | $5.21M | Add |
| Q2 2024 | 2.86M | $3.55M | Add |
| Q3 2024 | 5.00M | $3.78M | Add |
| Q4 2024 | 5.00M | $5.45M | Hold |
| Q1 2025 | 5.00M | $4.55M | Hold |
| Q2 2025 | 6.82M | $4.65M | Add |
| Q3 2025 | 6.82M | $4.90M | Hold |
| Q4 2025 | 6.82M | $2.08M | Hold |
| Q1 2026 | 6.82M | $1.57M | Hold |
| Q2 2026 | 370.68K | $11.70M | Reduce |
| Q3 2026 | 366.15K | $9.47M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CUE and 13F data
CUE (Cue Biopharma Inc) is a Health Care company. 32 other funds we track also report a position in CUE — the largest reported positions include Vivo Capital, LLC (US$7.2M), Tetragon Partners GP Ltd (US$3.0M), Lion Point Capital, LP (US$1.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CUE
- Vivo Capital, LLC 280.06K sh · $7.25M · Q3 2026
- Tetragon Partners GP Ltd 93.82K sh · $2.96M · Q2 2026
- Lion Point Capital, LP 52.93K sh · $1.67M · Q2 2026
- Squadron Capital Management LLC 50.00K sh · $1.58M · Q2 2026
More on Bleichroeder LP
FAQ
How long has Bleichroeder LP held CUE?
Bleichroeder LP has disclosed CUE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bleichroeder LP's current position in CUE?
As of Q3 2026, Bleichroeder LP holds 366.15K shares of CUE (Cue Biopharma Inc), valued at $9.47M, representing 0.95% of its reported portfolio and ranking #40.
Has Bleichroeder LP been buying or selling CUE?
In the latest 13F filing (Q3 2026), Bleichroeder LP reduced its position in CUE. The position peaked in Q2 2026 at 370.68K shares.
Which other funds hold CUE?
Other major institutional holders of CUE include Vivo Capital, LLC, Tetragon Partners GP Ltd, Lion Point Capital, LP, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.